This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cephalon Still a Stressor

Analysts had barely enough time to cheer -- comments ranged from "impressive" to "home run" -- when Cephalon and the FDA announced a strengthening of warnings for Provigil on Oct. 24. The sleep-disorders drug accounted for $415.5 million, or 47% of corporate revenue, for the first half of 2007. Patients and doctors are being warned about a rare, dangerous and sometimes fatal skin rash and about some reports of psychiatric problems, such as hallucinations and suicidal thoughts.

The back-to-back revelations for Treanda and Provigil is just one example of why some analysts get queasy, or at least prefer to sit on the sidelines until the swirling sensation subsides.

"A good deal of uncertainty surrounds Cephalon's new drugs, and the failure of a few launches could change the face of the company," says Karen Yiu, of the independent research firm Morningstar, in a report to clients late last month.

She cut her fair value to $64 a share from $77, thanks primarily to the poor performance of the alcoholism treatment Vivitrol. Initially, she said Vivitrol could produce peak annual sales of $500 million, but now she says it may average $200 million a year.

Cephalon markets Vivitrol for its developer Alkermes (ALKS). Vivitrol, a once-a-month injectable drug, was approved by the FDA in April 2006.

Although Cephalon has an "impressive" marketing record and roster of experimental drugs, Yiu worries about Nuvigil and Fentora. These drugs "may not succeed in the marketplace, and there is no guarantee that the firm's other drug programs will be able to pick up the slack if one of these drugs fails to live up to its potential," she says.

Fentora, approved by the FDA in September 2006, is the successor to Actiq. Both treat severe pain in cancer patients and both contain the powerful painkiller fentanyl.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,718.20 +40.30 0.24%
S&P 500 1,950.74 -0.08 -0.00%
NASDAQ 4,456.0710 +3.2790 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs